---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacodynamics"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacodynamics. Topics: Reduction of ESR1 variant mutations in circulating tumor DNA, Clinical benefit by change in ESR1 mutations, Ki67 and estrogen receptor expression in tumor samples, Exposure relative to the preclinical efficacy threshold, and 14 further topics. 18 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Reduction of ESR1 variant mutations in circulating tumor DNA

> “were reduced from 106 mutations detected at baseline (in 64 patients with detectable mutations at baseline) to 37 mutations (in 21 patients) after 2 treatment cycles of palazestrant treatment”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-2"></a>

### Clinical benefit by change in ESR1 mutations

> “In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-3"></a>

### Ki67 and estrogen receptor expression in tumor samples

> “Palazestrant treatment was associated with significantly reduced Ki67 levels from 29.2% (N = 18) to 20.4% (N = 12); P = 0.041”
> “resulted in a numerical decrease in ERα Allred score from 6.67 (N = 18) to 5.17 (N = 12); P = 0.13”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-4"></a>

### Exposure relative to the preclinical efficacy threshold

> “resulted in palazestrant concentrations above the predicted efficacy threshold of 226 ng/mL (Fig. 3), indicating complete inhibition of the ER”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-5"></a>

### Target engagement in a patient-derived xenograft

> “OP-1250 reduced Ki67 levels in a dose-dependent manner, in line with observed tumor growth inhibition”
> “At both the 5 and 10 mg/kg doses, nuclear ERα staining was reduced by approximately 75%, compared with the vehicle group, confirming target engagement”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-6"></a>

### Uterine wet weight assay

> “E2 and tamoxifen significantly increased UWW, while OP-1250 and fulvestrant did not. OP-1250 and fulvestrant inhibited E2-induced increases in weight, with OP-1250 displaying dose-dependent inhibition as low as 0.01 mg/kg”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-7"></a>

### Reversal of estrogen-induced transcription

> “OP-1250 treatment reversed E2-induced changes in transcriptional activity of known estrogen response genes within 6 hours”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-8"></a>

### Suppression of PGR and GREB1 expression

> “Palazestrant consistently downregulates PGR and GREB1 expression in both ESR1 wild-type (MCF7, CAMA-1) and mutant (ST941C) breast cancer models (Figure 6A-F).”

Source: [Barratt et al. (2026)](https://olema.com/wp-content/uploads/2026/04/Olema_AACR_2026_Poster-2950_Final-Digital-Poster.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### ESR1 wild-type xenograft

> “OP-1250 doses ≥3 mg/kg shrank tumors and outperformed fulvestrant, which did not lead to appreciable tumor shrinkage.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-10"></a>

### ESR1 Y537S patient-derived xenografts

> “In this model, OP-1250 doses of ≥1 mg/kg outperformed fulvestrant, and all treatments led to tumor growth inhibition; 10 and 30 mg/kg doses led to tumor shrinkage below starting volume in all treated animals”
> “Both OP-1250 doses outperformed elacestrant, with greatest tumor growth inhibition with 10 mg/kg OP-1250.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-11"></a>

### Intracranial xenograft model

> “4 of 8 animals in the OP-1250 monotherapy group and 6 of 8 in the OP-1250 + ribociclib group lacked detectable tumor at study day 100.”
> “OP-1250 treatment (monotherapy or in combination with ribociclib) resulted in all 8 animals alive at study day 100 and 6 alive 50 days after cessation of dosing.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-12"></a>

### Preclinical combination with CDK4/6 inhibitors

> “The 10 mg/kg dose of OP-1250, which leads to plasma concentrations similar to those measured in clinical studies, outperformed 75 mg/kg monotherapy doses of both CDK4/6 inhibitors and resulted in tumor shrinkage. Combination treatment resulted in more pronounced and consistent tumor shrinkage across doses, with all but one animal achieving >50% reduction in tumor volume”
> “addition of OP-1250 to either CDK4/6 inhibitor extended animal survival”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-13"></a>

### QTcF in the phase 1/2 monotherapy study

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-14"></a>

### Planned electrocardiogram analysis

> “The Corrected QT interval according to Fridericia’s formula (QTcF) and heart rate (HR) from electrocardiogram (ECG) data analysis will be conducted based on methodology recommended in the ICH E14 guideline”
> “Descriptive statistics (for the average of the triplicate measurements) at baseline and the maximum of post-baseline as well as changes from baseline will be summarized for QTcF and HR.”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="topic-2.1.2.6.2-15"></a>

### Bradycardia at the recommended phase 2 dose

> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-16"></a>

### Bradycardia during dose escalation

> “Four patients experienced grade 1 asymptomatic bradycardia; 1 of these 4 was found to have a prior history of asymptomatic bradycardia. One patient was in the 120 mg cohort, 1 patient was in the 210 mg cohort, and 2 patients were in the 300 mg cohort.”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.2-17"></a>

### QTcF in combination with ribociclib

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.6.2-18"></a>

### hERG inhibition in vitro

> “did not inhibit the human ether a-go-go related gene (hERG) protein at 30 μM and hence does not carry cardiac arrhythmia liability”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
